{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:04:50Z","timestamp":1788293090432,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014387","name":"Acadia Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009427","name":"Acadia University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009427","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jpet.2026.104932","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:01:49Z","timestamp":1777964509000},"page":"104932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nonclinical Characterization of ACP-204, a Novel Selective 5-HT2A Receptor Inverse Agonist"],"prefix":"10.1016","volume":"393","author":[{"given":"Ethan S.","family":"Burstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7107-3472","authenticated-orcid":false,"given":"Roger","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Skold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Erik","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Azar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7490-2494","authenticated-orcid":false,"given":"Christine","family":"Sandiego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1809-058X","authenticated-orcid":false,"given":"Khanum","family":"Ridler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-6687","authenticated-orcid":false,"given":"Eugenii A.","family":"Rabiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerry","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Markus","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5842-690X","authenticated-orcid":false,"given":"Sanjeev","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jpet.2026.104932_bib1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/13543784.2011.601738","article-title":"Serotonin 2A receptor antagonists for treatment of schizophrenia","volume":"20","author":"Ebdrup","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.1016\/j.jpet.2026.104932_bib2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1358\/dot.2010.46.3.1437247","article-title":"Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects","volume":"46","author":"Monti","year":"2010","journal-title":"Drugs Today (Barc)"},{"issue":"5","key":"10.1016\/j.jpet.2026.104932_bib3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1055\/s-2007-1017385","article-title":"The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam","volume":"18","author":"Ceulemans","year":"1985","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1016\/j.jpet.2026.104932_bib4","first-page":"111","article-title":"Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam","volume":"7","author":"Bressa","year":"1987","journal-title":"Int J Clin Pharmacol Res"},{"issue":"4","key":"10.1016\/j.jpet.2026.104932_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa2034634","article-title":"Trial of pimavanserin in dementia-related psychosis","volume":"385","author":"Tariot","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jpet.2026.104932_bib6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2215-0366(21)00386-2","article-title":"Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe","volume":"9","author":"Bugarski-Kirola","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"10.1016\/j.jpet.2026.104932_bib7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4088\/JCP.19m12928","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of adjunctive pimavanserin in patients with major depressive disorder and an inadequate response to therapy (CLARITY)","volume":"80","author":"Fava","year":"2019","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.jpet.2026.104932_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40264-022-01260-6","article-title":"Mortality in patients with Parkinson\u2019s disease-related psychosis treated with pimavanserin compared with other atypical antipsychotics: a cohort study","volume":"46","author":"Layton","year":"2023","journal-title":"Drug Saf"},{"issue":"8","key":"10.1016\/j.jpet.2026.104932_bib9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1176\/appi.ajp.21090876","article-title":"Mortality among Parkinson\u2019s disease patients treated with pimavanserin or atypical antipsychotics: an observational study in medicare beneficiaries","volume":"179","author":"Mosholder","year":"2022","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.jpet.2026.104932_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278262","article-title":"Assessing the risks of treatment in Parkinson disease psychosis: an in-depth analysis","volume":"18","author":"Longardner","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jpet.2026.104932_bib11","series-title":"NUPLAZID\u00ae (pimavanserin) prescribing information full prescribing information","year":"2025"},{"issue":"14","key":"10.1016\/j.jpet.2026.104932_bib12","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2174\/138161206776873662","article-title":"Integrative functional assays, chemical genomics and high throughput screening: harnessing signal transduction pathways to a common HTS readout","volume":"12","author":"Burstein","year":"2006","journal-title":"Curr Pharm Des"},{"issue":"3 Pt 1","key":"10.1016\/j.jpet.2026.104932_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/nimg.1996.0066","article-title":"Simplified reference tissue model for PET receptor studies","volume":"4","author":"Lammertsma","year":"1996","journal-title":"Neuroimage"},{"issue":"23","key":"10.1016\/j.jpet.2026.104932_bib14","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104932_bib15","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0022-3565(24)36840-5","article-title":"Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats","volume":"282","author":"Willins","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.jpet.2026.104932_bib16","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1177\/0091270007299431","article-title":"Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers","volume":"47","author":"Vanover","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"15","key":"10.1016\/j.jpet.2026.104932_bib17","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials","volume":"294","author":"Schneider","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jpet.2026.104932_bib18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","article-title":"Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials","volume":"14","author":"Schneider","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"issue":"15","key":"10.1016\/j.jpet.2026.104932_bib19","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa061240","article-title":"Effectiveness of atypical antipsychotic drugs in patients with Alzheimer\u2019s disease","volume":"355","author":"Schneider","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jpet.2026.104932_bib20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nrn1926","article-title":"Neuroleptic drugs in dementia: benefits and harm","volume":"7","author":"Ballard","year":"2006","journal-title":"Nat Rev Neurosci"},{"issue":"11","key":"10.1016\/j.jpet.2026.104932_bib21","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1176\/appi.ajp.162.11.2022","article-title":"Epidemiology of and risk factors for psychosis of Alzheimer\u2019s disease: a review of 55 studies published from 1990 to 2003","volume":"162","author":"Ropacki","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.jpet.2026.104932_bib22","first-page":"51","article-title":"Psychosis in dementia with Lewy bodies","volume":"3","author":"Morris","year":"1998","journal-title":"Semin Clin Neuropsychiatry"},{"issue":"5","key":"10.1016\/j.jpet.2026.104932_bib23","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/j.1582-4934.2011.01311.x","article-title":"Cerebral correlates of psychotic syndromes in neurodegenerative diseases","volume":"16","author":"Jellinger","year":"2012","journal-title":"J Cell Mol Med"},{"issue":"3","key":"10.1016\/j.jpet.2026.104932_bib24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","article-title":"Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects","volume":"46","author":"Holze","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"17","key":"10.1016\/j.jpet.2026.104932_bib25","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"NeuroReport"},{"issue":"1","key":"10.1016\/j.jpet.2026.104932_bib26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0022-3565(24)29327-7","article-title":"5-Hydroxytryptamine2A receptor inverse agonists as antipsychotics","volume":"299","author":"Weiner","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.jpet.2026.104932_bib27","first-page":"123","article-title":"M-100907 (Aventis)","volume":"2","author":"de Paulis","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"issue":"2 Suppl 1","key":"10.1016\/j.jpet.2026.104932_bib28","first-page":"242","article-title":"Clinical and PET effects of M100907, a selective 5HT-2A receptor antagonist","volume":"49","author":"Potkin","year":"2001","journal-title":"Schizophr Res"},{"issue":"6","key":"10.1016\/j.jpet.2026.104932_bib29","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder","volume":"161","author":"Meltzer","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jpet.2026.104932_bib30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1192\/bjp.163.4.451","article-title":"Ritanserin, a selective 5-HT2\/1C antagonist, and negative symptoms in schizophrenia. A placebocontrolled double-blind trial","volume":"163","author":"Duinkerke","year":"1993","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jpet.2026.104932_bib31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/bs.apha.2020.09.001","article-title":"A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia","volume":"90","author":"Snyder","year":"2021","journal-title":"Adv Pharmacol"},{"issue":"9916","key":"10.1016\/j.jpet.2026.104932_bib32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jpet.2026.104932_bib33","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1007\/s11064-014-1293-3","article-title":"On the discovery and development of pimavanserin: a novel drug candidate for Parkinson\u2019s psychosis","volume":"39","author":"Hacksell","year":"2014","journal-title":"Neurochem Res"},{"issue":"3","key":"10.1016\/j.jpet.2026.104932_bib34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","article-title":"Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer\u2019s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study","volume":"17","author":"Ballard","year":"2018","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104932_bib35","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1177\/13872877251345162","article-title":"Pimavanserin safety in adult and elderly patients with neuropsychiatric symptoms related to neurodegenerative disease: an open-label extension study","volume":"106","author":"Cuba\u0142a","year":"2025","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.jpet.2026.104932_bib36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3233\/JAD-231167","article-title":"Safety profile of pimavanserin therapy in elderly patients with neurodegenerative disease-related neuropsychiatric symptoms: a phase 3B study","volume":"98","author":"Alva","year":"2024","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jpet.2026.104932_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.892199","article-title":"Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia","volume":"13","author":"Bugarski-Kirola","year":"2022","journal-title":"Front Psychiatry"},{"issue":"5","key":"10.1016\/j.jpet.2026.104932_bib38","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/cpdd.1232","article-title":"Exposure-response modeling from the CLARITY trial of pimavanserin for adjunctive treatment of major depressive disorder","volume":"12","author":"Darwish","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"10.1016\/j.jpet.2026.104932_bib39","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/JCP.0000000000001611","article-title":"Pimavanserin exposure-response analyses in patients with schizophrenia: results from the phase 2 advance study","volume":"42","author":"Darwish","year":"2022","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104932_bib40","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/jpet.105.097006","article-title":"Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N\u2032-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist","volume":"317","author":"Vanover","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2026.104932_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2019.134524","article-title":"Inverse agonists of the 5-HT2A receptor reduce nicotine withdrawal signs in rats","volume":"713","author":"Malin","year":"2019","journal-title":"Neurosci Lett"},{"issue":"26","key":"10.1016\/j.jpet.2026.104932_bib42","doi-asserted-by":"crossref","first-page":"8836","DOI":"10.1523\/JNEUROSCI.23-26-08836.2003","article-title":"Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex","volume":"23","author":"Gonz\u00e1lez-Maeso","year":"2003","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.jpet.2026.104932_bib43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00213-003-1549-0","article-title":"The 5-HT2A receptor antagonist M100,907 attenuates motor and \u201cimpulsive-type\u201d behaviours produced by NMDA receptor antagonism","volume":"170","author":"Higgins","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"10.1016\/j.jpet.2026.104932_bib44","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00008877-199512000-00010","article-title":"DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT(2A) and not by 5-HT(2C) receptors","volume":"6","author":"Sipes","year":"1995","journal-title":"Behav Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104932_bib45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0006-8993(97)00316-8","article-title":"DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum","volume":"761","author":"Sipes","year":"1997","journal-title":"Brain Res"},{"issue":"5","key":"10.1016\/j.jpet.2026.104932_bib46","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/jcbfm.1995.99","article-title":"Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls","volume":"15","author":"Sadzot","year":"1995","journal-title":"J Cereb Blood Flow Metab"},{"issue":"6","key":"10.1016\/j.jpet.2026.104932_bib47","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s00259-006-0296-y","article-title":"Reproducibility of 5-HT2A receptor measurements and sample size estimations with [18F]altanserin PET using a bolus\/infusion approach","volume":"34","author":"Haugb\u00f8l","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.jpet.2026.104932_bib48","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13550-020-00718-x","article-title":"Blocking of efflux transporters in rats improves translational validation of brain radioligands","volume":"10","author":"Shalgunov","year":"2020","journal-title":"EJNMMI Res"},{"issue":"8","key":"10.1016\/j.jpet.2026.104932_bib49","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s12149-021-01633-4","article-title":"Measurement of changes in endogenous serotonin level by positron emission tomography with [18F]altanserin","volume":"35","author":"Ikoma","year":"2021","journal-title":"Ann Nucl Med"},{"issue":"2","key":"10.1016\/j.jpet.2026.104932_bib50","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/0271678X241276312","article-title":"Imaging the 5-HT2C receptor with PET: evaluation of 5-HT2C and 5-HT2A affinity of pimavanserin in the primate brain","volume":"45","author":"Ridler","year":"2025","journal-title":"J Cereb Blood Flow Metab"},{"issue":"2","key":"10.1016\/j.jpet.2026.104932_bib51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1461145707007869","article-title":"PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain","volume":"11","author":"Nordstrom","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104932_bib52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00213-022-06293-4","article-title":"Antipsychotics and risk of QT prolongation: a pharmacovigilance study","volume":"240","author":"Bordet","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2026.104932_bib53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2005.01.009","article-title":"Effect of trazodone on hERG channel current and QT-interval","volume":"510","author":"Tarantino","year":"2005","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104932_bib54","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/bjp.2008.261","article-title":"The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-\u00e0-go-go-related gene (hERG) potassium channels","volume":"155","author":"Tang","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104932_bib55","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF00609240","article-title":"The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension","volume":"35","author":"Stott","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104932_bib56","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0022-3565(25)12319-7","article-title":"Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872","volume":"276","author":"Bril","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.jpet.2026.104932_bib57","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1292\/jvms.09-0397","article-title":"Changes in the gene expression and enzyme activity of hepatic cytochrome P450 in juvenile Sprague-Dawley rats","volume":"72","author":"Asaoka","year":"2010","journal-title":"J Vet Med Sci"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T08:07:49Z","timestamp":1782720469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526011316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0022356526011316"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104932","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonclinical Characterization of ACP-204, a Novel Selective 5-HT2A Receptor Inverse Agonist","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104932","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"104932"}}